Crystal structures of the M1 and M4 muscarinic acetylcholine receptors

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Nature

• Publication date

  2016-03-09

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1038/nature17188PMID 26958838PMCID PMC4915387
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Development of a Radioligand, [3H]LY2119620, to Probe the Human M2 and M4 Muscarinic Receptor Allosteric Binding Sites

  2014cited by this paper
• Modified T4 Lysozyme Fusion Proteins Facilitate G Protein-Coupled Receptor Crystallogenesis.

  2014cited by this paper
• Molecular Determinants of Allosteric Modulation at the M1 Muscarinic Acetylcholine Receptor*

  2014cited by this paper
• Muscarinic acetylcholine receptor X-ray structures: potential implications for drug development.

  2014cited by this paper
• Muscarinic acetylcholine receptors: novel opportunities for drug development

  2014cited by this paper
• Mechanistic Insights into Allosteric Structure-Function Relationships at the M1 Muscarinic Acetylcholine Receptor*

  2014cited by this paper
• Allosteric and Biased G Protein-Coupled Receptor Signaling Regulation: Potentials for New Therapeutics

  2014cited by this paper
• Characterization of the Novel Positive Allosteric Modulator, LY2119620, at the Muscarinic M2 and M4 Receptors

  2014cited by this paper
• Activation and allosteric modulation of a muscarinic acetylcholine receptor

  2013cited by this paper
• Molecular basis for the long duration of action and kinetic selectivity of tiotropium for the muscarinic M3 receptor.

  2013cited by this paper
• ConSurf: Using Evolutionary Data to Raise Testable Hypotheses about Protein Function

  2013cited by this paper
• Emerging approaches for treatment of schizophrenia: modulation of cholinergic signaling.

  2012cited by this paper
• Fusion partner toolchest for the stabilization and crystallization of G protein-coupled receptors.

  2012cited by this paper
• Linking Crystallographic Model and Data Quality

  2012cited by this paper
• Structure and Dynamics of the M3 Muscarinic Acetylcholine Receptor

  2012cited by this paper
• The Role of Transmembrane Domain 3 in the Actions of Orthosteric, Allosteric, and Atypical Agonists of the M4 Muscarinic Acetylcholine Receptor

  2011cited by this paper
• SwissDock, a protein-small molecule docking web service based on EADock DSS

  2011cited by this paper
• Impact of species variability and ‘probe‐dependence’ on the detection and in vivo validation of allosteric modulation at the M4 muscarinic acetylcholine receptor

  2011cited by this paper
• Allosteric modulation of G protein-coupled receptors: a pharmacological perspective.

  2011cited by this paper
• Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist

  2011cited by this paper
• Structural Determinants of Allosteric Agonism and Modulation at the M4 Muscarinic Acetylcholine Receptor

  2010cited by this paper
• Molecular Mechanisms of Action and In Vivo Validation of an M4 Muscarinic Acetylcholine Receptor Allosteric Modulator with Potential Antipsychotic Properties

  2010cited by this paper
• Allosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders.

  2010cited by this paper
• ConSurf 2010: calculating evolutionary conservation in sequence and structure of proteins and nucleic acids

  2010cited by this paper
• Features and development of Coot

  2010cited by this paper
• Allosteric Modulation of Muscarinic Acetylcholine Receptors

  2010cited by this paper
• Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists.

  2009cited by this paper
• A Selective Allosteric Potentiator of the M1 Muscarinic Acetylcholine Receptor Increases Activity of Medial Prefrontal Cortical Neurons and Restores Impairments in Reversal Learning

  2009cited by this paper
• MolProbity: all-atom structure validation for macromolecular crystallography

  2009cited by this paper
• Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders.

  2009cited by this paper
• Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation

  2009cited by this paper
• Automated comparative protein structure modeling with SWISS‐MODEL and Swiss‐PdbViewer: A historical perspective

  2009cited by this paper
• Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders

  2009cited by this paper
• Crystallizing membrane proteins using lipidic mesophases

  2009cited by this paper
• New Insights into the Function of M4 Muscarinic Acetylcholine Receptors Gained Using a Novel Allosteric Modulator and a DREADD (Designer Receptor Exclusively Activated by a Designer Drug)

  2008cited by this paper
• Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia

  2008cited by this paper
• Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia.

  2008cited by this paper
• Critical Role for the Second Extracellular Loop in the Binding of Both Orthosteric and Allosteric G Protein-coupled Receptor Ligands*

  2007cited by this paper
• Phaser crystallographic software

  2007cited by this paper
• Clustal W and Clustal X version 2.0

  2007cited by this paper
• PDB2PQR: expanding and upgrading automated preparation of biomolecular structures for molecular simulations

  2007cited by this paper
• Cholinergic modulation of cortical function

  2007cited by this paper
• Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development

  2007cited by this paper
• Multiple Residues in the Second Extracellular Loop Are Critical for M3 Muscarinic Acetylcholine Receptor Activation*

  2007cited by this paper
• Roof and Floor of the Muscarinic Binding Pocket: Variations in the Binding Modes of Orthosteric Ligands

  2007cited by this paper
• Allosteric Modulation of Muscarinic Acetylcholine Receptors

  2007cited by this paper
• The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling

  2006cited by this paper
• The role of acetylcholine in learning and memory.

  2006cited by this paper
• Structural Genomics

  2005cited by this paper
• ConSurf 2005: the projection of evolutionary conservation scores of residues on protein structures

  2005cited by this paper
• Direct incorporation of experimental phase information in model refinement.

  2004cited by this paper
• Fitting Models to Biological Data Using Linear and Nonlinear Regression: A Practical Guide to Curve Fitting

  2004cited by this paper
• PDB2PQR: an automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations

  2004cited by this paper
• research papers Acta Crystallographica Section D Biological

  2003cited by this paper
• The PyMOL Molecular Graphics System

  2002cited by this paper
• Electrostatics of nanosystems: Application to microtubules and the ribosome

  2001cited by this paper
• Transmembrane Domains 4 and 7 of the M1Muscarinic Acetylcholine Receptor Are Critical for Ligand Binding and the Receptor Activation Switch*

  2001cited by this paper
• Correspondence e-mail:

  2000cited by this paper
• Site-directed mutagenesis reveals two epitopes involved in the subtype selectivity of the allosteric interactions of gallamine at muscarinic acetylcholine receptors.

  1999cited by this paper
• Evolutionarily conserved pathways of energetic connectivity in protein families.

  1999cited by this paper
• International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors.

  1998cited by this paper
• Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease.

  1997cited by this paper
• Molecular architecture of G protein‐coupled receptors

  1996cited by this paper
• Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods.

  1988cited by this paper
• Modification of the binding properties of muscarinic receptors by gallamine.

  1983cited by this paper
• Electronic Reprint Biological Crystallography Phenix : a Comprehensive Python-based System for Macromolecular Structure Solution

  year unknowncited by this paper

• Cholesterol differentially modulates the activity of opioid and muscarinic receptors via a common binding site

  2025cites this paper
• Is muscarinic receptor agonist effective and tolerant for schizophrenia?

  2025cites this paper
• Effect of hexyloxy position on antagonistic properties of KH-5 (1-{2-[4-(hexyloxy)benzoyloxy]ethyl}-1-methyl-1,2,3,6-tetrahydropyridin-1-ium iodide) at muscarinic acetylcholine receptors.

  2025cites this paper
• Acetylcholine receptors (muscarinic) in GtoPdb v.2025.3

  2025cites this paper
• Functional dynamics of G protein-coupled receptors reveal new routes for drug discovery

  2025cites this paper
• G protein-coupled receptors: A golden key to the treasure-trove of neurodegenerative diseases.

  2025cites this paper
• Bile Acids Are Potential Negative Allosteric Modulators of M1 Muscarinic Receptors

  2025influential citation
• A Meta-Analysis of In Vitro Release of Hydrophilic Therapeutics from Contact Lenses Using Mathematical Modeling

  2025cites this paper
• Role of the neurotransmitter-receptor pathway in T-cell tumor immunology and cancer immunotherapy

  2025cites this paper
• Design, synthesis, and pharmacological evaluation of novel M4 muscarinic receptor positive allosteric modulators for schizophrenia treatment.

  2025cites this paper
• Activation dynamics traced through a G protein-coupled receptor by 81 1H-15N NMR probes.

  2025cites this paper
• Allosteric modulation of laeviganoid-based clerodane diterpenes derivatives in muscarinic acetylcholine M1 receptor against tinnitus: a structure-based virtual screening approach

  2025cites this paper
• Systems Biology Approach to Berberine Metabolomics and Toxicity: An In Silico Investigation of Bioactive Pathways and Risk Assessment.

  2025cites this paper
• M1 receptor positive allosteric modulators discovery approaches.

  2025cites this paper
• Visualizing agonist-induced M2 receptor activation regulated by aromatic ring dynamics

  2025cites this paper
• From pharmacophore predictions to pharmaceutical possibilities: an integrated approach to screen M3 selective muscarinic receptor antagonist

  2025cites this paper
• Balancing Rigidity and Flexibility: Optimised 4-(Hexyloxy)benzoate Antagonists with Enhanced Affinity and Tuneable Duration at Muscarinic Receptors

  2025cites this paper
• The Prosperity and Adversity of M4 Muscarinic Acetylcholine Receptor Activators in the Treatment of Neuropsychiatric Disorders.

  2025cites this paper
• Hybrid Allosteric Modulators of M1 Muscarinic Receptors Enhance Acetylcholine Efficacy and Decrease Locomotor Activity and Turning Behaviors in Zebrafish

  2024cites this paper
• Analysing the effect caused by increasing the molecular volume in M1-AChR receptor agonists and antagonists: a structural and computational study

  2024cites this paper
• A golden age of muscarinic acetylcholine receptor modulation in neurological diseases

  2024cites this paper
• Design and Synthesis of Clinical Candidate PF-06852231 (CVL-231): A Brain Penetrant, Selective, Positive Allosteric Modulator of the M4 Muscarinic Acetylcholine Receptor.

  2024cites this paper
• Identification of Psychoplastogenic Tropanes Lacking Muscarinic Activity.

  2024cites this paper
• Current Progress on Central Cholinergic Receptors as Therapeutic Targets for Alzheimer's Disease.

  2024cites this paper
• G Protein-Coupled Receptor–Ligand Pose and Functional Class Prediction

  2024cites this paper
• Bivalent and bitopic ligands of the opioid receptors: The prospects of a dual approach

  2024cites this paper
• Interaction of twenty-two carbazole derivatives with M1-muscarinic receptor using a theoretical model

  2024cites this paper
• The rapeutic impact of alkaloids in neurological diseases: A promising key molecule

  2024cites this paper
• New potent muscarinic receptor ligands bearing the 1,4‐dioxane nucleus: Investigation on the nature of the substituent in position 2

  2024cites this paper
• Visualizing the M2 muscarinic acetylcholine receptor activation regulated by aromatic ring dynamics

  2024cites this paper
• Extracellular Peptide-Ligand Dimerization Actuator Receptor Design for Reversible and Spatially Dosed 3D Cell-Material Communication

  2024cites this paper
• Deepening insights into cholinergic agents for intraocular pressure reduction: systems genetics, molecular modeling, and in vivo perspectives

  2024cites this paper
• REvoLd: Ultra-Large Library Screening with an Evolutionary Algorithm in Rosetta.

  2024cites this paper
• Ligand bias at the muscarinic acetylcholine receptor family: opportunities and challenges.

  2024cites this paper
• Exploring structure-based drug discovery of GPCRs beyond the orthosteric binding site

  2024cites this paper
• Allosteric modulators of M1 muscarinic receptors enhance acetylcholine efficacy and decrease locomotor activity and turning behaviors in zebrafish

  2024cites this paper
• De novo design of a fusion protein tool for GPCR research

  2024cites this paper
• Ultra-large library screening with an evolutionary algorithm in Rosetta (REvoLd)

  2024cites this paper
• Positive allosteric modulation of a GPCR ternary complex

  2024cites this paper
• M1/M4 receptors as potential therapeutic treatments for schizophrenia: A comprehensive study.

  2024cites this paper
• Synthesis and nootropic activity prediction of some 4-(aminomethyl)-1-benzylpyrrolidin-2-one derivatives structurally related with nebracetam

  2024cites this paper
• The central renin–angiotensin system: A genetic pathway, functional decoding, and selective target engagement characterization in humans

  2024cites this paper
• Agonist-selective activation of individual G-proteins by muscarinic receptors

  2024cites this paper
• Entropy drives the ligand recognition in G-protein-coupled receptor subtypes

  2024cites this paper
• Deep Learning Dynamic Allostery of G-Protein-Coupled Receptors

  2023cites this paper
• Allosteric Sites and Allosteric Regulators of G Protein-Coupled Receptors: Gray Cardinals of Signal Transduction

  2023cites this paper
• Deep Learning Dynamic Allostery of G-Protein-Coupled Receptors

  2023cites this paper
• Developing anticholinergic drugs for the treatment of asthma with improved efficacy

  2023cites this paper
• Transaminases Provide Key Chiral Building Blocks for the Synthesis of Selective M1/M4 Agonists.

  2023cites this paper
• A Novel "Activation Switch" Motif Common to All Aminergic Receptors

  2023cites this paper
• Structure-based pharmacophore modeling 2. Developing a novel framework for structure-based pharmacophore model generation and selection.

  2023cites this paper
• Cymbopogon citratus Essential Oil: Extraction, GC–MS, Phytochemical Analysis, Antioxidant Activity, and In Silico Molecular Docking for Protein Targets Related to CNS

  2023cites this paper
• Molecular Biophysics of Class A G Protein Coupled Receptors–Lipids Interactome at a Glance—Highlights from the A2A Adenosine Receptor

  2023cites this paper
• Role of Conserved Tyrosine Lid Residues in the Activation of the M2 Muscarinic Acetylcholine Receptor

  2023cites this paper
• Imaging Cholinergic Receptors in the Brain by Positron Emission Tomography

  2023cites this paper
• Advances of computer-aided drug design (CADD) in the development of anti-Azheimer's-disease drugs.

  2023cites this paper
• Design, synthesis and evaluation of novel 2-phenyl-3-(1H-pyrazol-4-yl)pyridine positive allosteric modulators for the M4 mAChR.

  2023cites this paper
• Improving the Modeling of Extracellular Ligand Binding Pockets in RosettaGPCR for Conformational Selection

  2023cites this paper
• Structural basis of efficacy-driven ligand selectivity at GPCRs

  2023cites this paper
• Deep Learning Dynamic Allostery of G-Protein-Coupled Receptors

  2023cites this paper
• Structural and dynamic insights into supra-physiological activation and allosteric modulation of a muscarinic acetylcholine receptor

  2023cites this paper
• Structure-based pharmacophore modeling 1. Automated random pharmacophore model generation.

  2023cites this paper
• Novel Xanomeline-Containing Bitopic Ligands of Muscarinic Acetylcholine Receptors: Design, Synthesis and FRET Investigation

  2023cites this paper
• Rapid Synthesis of Psychoplastogenic Tropane Alkaloids

  2023cites this paper
• Pharmacological hallmarks of allostery at the M4 muscarinic receptor elucidated through structure and dynamics

  2023cites this paper
• Targeting muscarinic receptors for the treatment of alcohol use disorders: Opportunities and hurdles for clinical development

  2023cites this paper
• Xanomeline displays concomitant orthosteric and allosteric binding modes at the M4 mAChR

  2023influential citation
• Modeling defensive functions of alkaloids within diverse chemical portfolios

  2023cites this paper
• Antagonism of the Muscarinic Acetylcholine Type 1 Receptor Enhances Mitochondrial Membrane Potential and Expression of Respiratory Chain Components via AMPK in Human Neuroblastoma SH-SY5Y Cells and Primary Neurons

  2022cites this paper
• Multitargeting nature of muscarinic orthosteric agonists and antagonists

  2022influential citation
• Comparative studies of AlphaFold, RoseTTAFold and Modeller: a case study involving the use of G-protein-coupled receptors

  2022cites this paper
• Function and structure of bradykinin receptor 2 for drug discovery

  2022cites this paper
• Mechanistic insight of the potential of geraniol against Alzheimer’s disease

  2022cites this paper
• Pharmacological hallmarks of allostery at the M4 muscarinic receptor elucidated through structure and dynamics

  2022cites this paper
• Triangular Contrastive Learning on Molecular Graphs

  2022influential citation
• Muscarinic Acetylcholine Receptor Agonists as Novel Treatments for Schizophrenia.

  2022cites this paper
• The unconventional activation of the muscarinic acetylcholine receptor M4R by diverse ligands

  2022cites this paper
• Intrinsically disordered proteins and proteins with intrinsically disordered regions in neurodegenerative diseases

  2022cites this paper
• Loss of Cholinergic Receptor Muscarinic 1 (CHRM1) Protein in the Hippocampus and Temporal Cortex of a Subset of Individuals with Alzheimer’s Disease, Parkinson’s Disease, or Frontotemporal Dementia: Implications for Patient Survival

  2022cites this paper
• MD Simulations Revealing Special Activation Mechanism of Cannabinoid Receptor 1

  2022cites this paper
• Design, Synthesis, and Biological Evaluation of 4,4’-Difluorobenzhydrol Carbamates as Selective M1 Antagonists

  2022cites this paper
• Structural basis of GPCR coupling to distinct signal transducers: implications for biased signaling.

  2022cites this paper
• Crystal structure of the α1B-adrenergic receptor reveals molecular determinants of selective ligand recognition

  2022cites this paper
• Cryo-EM structures of human bradykinin receptor-Gq proteins complexes

  2022cites this paper
• Targeting the M1 muscarinic acetylcholine receptor in Alzheimer’s disease

  2022cites this paper
• MT9, a natural peptide from black mamba venom antagonizes the muscarinic type 2 receptor and reverses the M2R-agonist-induced relaxation in rat and human arteries.

  2022cites this paper
• Modulation of Muscarinic Signalling in the Central Nervous System by Steroid Hormones and Neurosteroids

  2022cites this paper
• N-[1,3-Dialkyl(aryl)-2-oxoimidazolidin-4-ylidene]-aryl(alkyl)sulphonamides as Novel Selective Human Cannabinoid Type 2 Receptor (hCB2R) Ligands; Insights into the Mechanism of Receptor Activation/Deactivation

  2022cites this paper
• Simplified quality assessment for small-molecule ligands in the Protein Data Bank.

  2022cites this paper
• Novel Molecular Targets of Antidepressants

  2022cites this paper
• Opportunities and challenges for the development of M1 muscarinic receptor positive allosteric modulators in the treatment for neurocognitive deficits

  2022cites this paper
• Drug Design Targeting the Muscarinic Receptors and the Implications in Central Nervous System Disorders

  2022influential citation
• The Impact of the Secondary Binding Pocket on the Pharmacology of Class A GPCRs

  2022cites this paper
• An in silico and in vitro integrated analysis method to reveal the curative mechanisms and pharmacodynamic substances of Bufei granule on chronic obstructive pulmonary disease

  2022cites this paper
• Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic.

  2022cites this paper
• Structural insights into adhesion GPCR ADGRL3 activation and Gq, Gs, Gi, and G12 coupling.

  2022cites this paper
• Structural basis for recognition of antihistamine drug by human histamine receptor

  2022cites this paper
• Network toxicology and molecular docking analyses on strychnine indicate CHRM1 is a potential neurotoxic target

  2022cites this paper
• An Integrated Machine Learning Model To Spot Peptide Binding Pockets in 3D Protein Screening

  2022cites this paper
• Synthesis, docking, and biological evaluation of novel 1-benzyl-4-(4-(R)-5-sulfonylidene-4,5-dihydro-1H-1,2,4-triazol-3-yl)pyrrolidin-2-ones as potential nootropic agents.

  2022cites this paper